12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zyclara imiquimod regulatory update

The European Commission approved an MAA for Zyclara imiquimod 3.75% from Meda to treat actinic keratosis (AK) on large skin areas. Meda said it plans to launch the product in Europe early next year. The immune response modifier is approved in...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >